BTIG Reiterates Buy on Medline, Maintains $55 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.0%

Neg 0% Neu 88% Pos 0%

BTIG analyst David Larsen reiterates Medline (NASDAQ:MDLN) with a Buy and maintains $55 price target.

Comments

No comments yet. Be the first!